KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Capital ExpendituresCapital ExpendituresCash from Financing ActivitiesCash from Financing ActivitiesCash from Investing ActivitiesCash from Investing ActivitiesCash from OperationsCash from OperationsChange in Accured ExpensesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in InventoryChange in ReceivablesChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Depreciation & Amortization (CF)Exchange Rate EffectExchange Rate EffectFree Cash FlowFree Cash FlowGains from Investment SecuritiesGains from Investment SecuritiesLong-Term Debt IssuancesLong-Term Debt RepaymentsNet Cash FlowNet Cash FlowNet IncomeOther Working Capital ChangesOther Working Capital ChangesOther financing activitiesOther financing activitiesShare-based CompensationShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Alnylam Pharmaceuticals (ALNY) Share-based Compensation (2016 - 2026)

Alnylam Pharmaceuticals (ALNY) has disclosed Share-based Compensation for 18 consecutive years, with $70.2 million as the latest value for Q1 2026.

  • For Q1 2026, Share-based Compensation rose 23.7% year-over-year to $70.2 million; the TTM value through Mar 2026 reached $361.7 million, up 27.6%, while the annual FY2025 figure was $348.2 million, 27.99% up from the prior year.
  • Share-based Compensation hit $70.2 million in Q1 2026 for Alnylam Pharmaceuticals, down from $71.6 million in the prior quarter.
  • Across five years, Share-based Compensation topped out at $128.1 million in Q3 2022 and bottomed at $29.3 million in Q1 2022.
  • Average Share-based Compensation over 5 years is $67.2 million, with a median of $63.9 million recorded in 2023.
  • Year-over-year, Share-based Compensation surged 283.97% in 2022 and then crashed 50.1% in 2023.
  • Alnylam Pharmaceuticals' Share-based Compensation stood at $42.8 million in 2022, then fell by 1.81% to $42.0 million in 2023, then surged by 118.23% to $91.6 million in 2024, then fell by 21.84% to $71.6 million in 2025, then decreased by 2.06% to $70.2 million in 2026.
  • According to Business Quant data, Share-based Compensation over the past three periods came in at $70.2 million, $71.6 million, and $108.2 million for Q1 2026, Q4 2025, and Q3 2025 respectively.